SPOSAB ABP 501 – A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

Posted on February 5, 2021 by Gastroenterology Journal

There are few clinical data on Adalimumab (ADA) biosimilars in inflammatory bowel disease.

This entry was posted in News. Bookmark the permalink.